Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cell Constructs is a U.S.-based regenerative wound care company that rebranded as ProgenaCare Global in 2021. The company develops advanced wound care products and related biomaterial technologies centered on a human keratin platform, with a focus on improving healing in chronic and acute wounds. Its lead commercial product is ProgenaMatrix, a human keratin matrix for wound treatment, and its portfolio has also included revyve Antimicrobial Wound Gel. Earlier company materials also described autologous stem cell therapy concepts combined with proprietary biomaterials, although the more recent commercial focus appears to be medical-device-based wound care. The business operates in the advanced wound care and regenerative medicine segment and appears to remain active as a private company under the ProgenaCare Global name.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cell Constructs.